Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 6Phase NA 5Phase 2/3 2Phase 1 2Phase 4 1

Status

Unknown 9Recruiting 7Not yet recruiting 5Active not recruiting 4Withdrawn 1Terminated 1

Sponsor Class

OTHER 7

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 311Carcinoma, Non-Small-Cell Lung 282Prostatic Neoplasms 160Colorectal Neoplasms 155Carcinoma, Hepatocellular 144Neoplasms 134Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 108Triple Negative Breast Neoplasms 102Multiple Myeloma 102Recurrence 99Pancreatic Neoplasms 94Stomach Neoplasms 93Ovarian Neoplasms 87Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Rectal Neoplasms 62Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 57Lymphoma 55Myelodysplastic Syndromes 54Esophageal Squamous Cell Carcinoma 54

Interventions

pyrotinib 4Trastuzumab 2tucatinib 1trastuzumab deruxtecan 1inavolisib 1Neoadjuvant Therapy 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × HER2-positive Breast Cancer × Clear all
NCT05982678 2025-11-26

ANISE

The Netherlands Cancer Institute

Phase 2 Recruiting
72 enrolled
Breast

HER2-positive Breast Cancer

NCT05955170 2025-03-27

TUC-TOC

Institut Curie

Phase 2 Recruiting
66 enrolled
Breast

HER2-positive Breast Cancer

NCT06832904 2025-02-18

Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
33 enrolled
Breast

HER2-positive Breast Cancer

NCT05306041 2025-02-17

GeparPiPPa

GBG Forschungs GmbH

Phase 2 Recruiting
170 enrolled
Breast

HER2-positive Breast Cancer

NCT05635487 2024-07-05

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2 Recruiting
65 enrolled
Breast

HER2-positive Breast Cancer

NCT05834764 2023-04-28

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
188 enrolled
Breast

HER2-positive Breast Cancer

NCT04481932 2020-07-22

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Peking University

Phase 2 Recruiting
104 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡